West Announces Fourth-Quarter and Full-Year 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance
February 17, 2022 6:08 AM ESTWest Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.13 better than the analyst estimate of $1.91. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $710.2 million.
GUIDANCE:
West Pharma sees FY2022 EPS of $9.20-$9.35, versus the consensus of... More



